SAB Biotherapeutics (SABS) Construction in Progress (2021 - 2023)

SAB Biotherapeutics has reported Construction in Progress for 3 years, with the latest figure at $137811.0 in Q1 2023.

• For the quarter ending Q1 2023, Construction in Progress changed N/A year-over-year to $137811.0; the trailing twelve-month figure through Mar 2023 stood at $137811.0 (changed N/A YoY), and the FY2022 full-year result was $84739.0, down 65.67% from the prior year.
• Construction in Progress for Q1 2023 stood at $137811.0, up from $84739.0 in the prior quarter.
• The five-year high for Construction in Progress was $246801.0 in Q4 2021, with the low at $84739.0 in Q4 2022.
• Historically, Construction in Progress has averaged $156450.3 across 3 years, with a median of $137811.0 in 2023.
• The largest YoY upside for Construction in Progress was 65.67% in 2022 against a maximum downside of 65.67% in 2022.
• SAB Biotherapeutics' Construction in Progress stood at $246801.0 in 2021, then plunged by 65.67% to $84739.0 in 2022, then surged by 62.63% to $137811.0 in 2023.
• The last three Construction in Progress figures came in at $137811.0 (Q1 2023), $84739.0 (Q4 2022), and $246801.0 (Q4 2021), per Business Quant data.